Janney Montgomery Scott LLC Raises Stock Position in CVS Health Corporation (NYSE:CVS)

Janney Montgomery Scott LLC boosted its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 21.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 315,098 shares of the pharmacy operator's stock after buying an additional 56,156 shares during the quarter. Janney Montgomery Scott LLC's holdings in CVS Health were worth $21,348,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. McIlrath & Eck LLC boosted its stake in CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 174 shares in the last quarter. Coppell Advisory Solutions LLC boosted its position in shares of CVS Health by 17.3% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock worth $56,000 after purchasing an additional 189 shares in the last quarter. EagleClaw Capital Managment LLC grew its stake in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after buying an additional 200 shares during the last quarter. Angeles Investment Advisors LLC increased its position in CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock valued at $256,000 after buying an additional 204 shares in the last quarter. Finally, Beck Mack & Oliver LLC raised its stake in CVS Health by 1.1% in the fourth quarter. Beck Mack & Oliver LLC now owns 20,425 shares of the pharmacy operator's stock valued at $917,000 after buying an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

CVS Health stock traded down $0.19 during midday trading on Thursday, hitting $66.91. 5,208,935 shares of the company were exchanged, compared to its average volume of 10,943,569. The business has a fifty day simple moving average of $65.02 and a two-hundred day simple moving average of $60.30. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a market capitalization of $84.64 billion, a PE ratio of 15.97, a price-to-earnings-growth ratio of 0.96 and a beta of 0.56. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same quarter last year, the company earned $1.31 EPS. The business's revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were purchased at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the transaction, the director now directly owns 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.22% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent analyst reports. Mizuho upped their price objective on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. UBS Group boosted their price objective on shares of CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Morgan Stanley reissued an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Finally, Cowen reaffirmed a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $74.75.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.